Get the Stockscreener App
43.50
3.76%
-1.70
After Hours:
43.50
Veracyte Inc stock is traded at $43.50, with a volume of 617.19K.
It is down -3.76% in the last 24 hours and up +0.21% over the past month.
See More
Previous Close:
$45.20
Open:
$45.45
24h Volume:
617.19K
Relative Volume:
0.81
Market Cap:
$3.29B
Revenue:
$399.58M
Net Income/Loss:
$-54.04M
P/E Ratio:
-58.00
EPS:
-0.75
Net Cash Flow:
$40.13M
1W Performance:
-5.72%
1M Performance:
+0.21%
6M Performance:
+99.36%
1Y Performance:
+70.92%
1-Day Range:
$43.23
$46.50
1-Week Range:
$42.89
$46.50
52-Week Range:
$18.61
$47.32
Veracyte Inc Stock (VCYT) Company Profile
Name
Veracyte Inc
Sector
Industry
Phone
(650) 243-6300
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
43.50 | 3.29B | 399.58M | -54.04M | 40.13M | -0.75 |
|
TMO
Thermo Fisher Scientific Inc
|
572.71 | 219.06B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
210.01 | 151.02B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
147.64 | 42.12B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
209.96 | 38.11B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
460.56 | 37.71B | 3.84B | 866.24M | 792.60M | 10.37 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-16-24 | Initiated | UBS | Buy |
| Oct-10-24 | Initiated | Guggenheim | Buy |
| Feb-23-24 | Reiterated | Needham | Buy |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Nov-18-21 | Resumed | Goldman | Buy |
| Jun-15-21 | Initiated | Raymond James | Outperform |
| Feb-18-21 | Resumed | Needham | Buy |
| Jan-28-21 | Initiated | Truist | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-09-20 | Initiated | Morgan Stanley | Underweight |
| Jul-31-19 | Initiated | Lake Street | Buy |
| Jul-02-19 | Initiated | Needham | Buy |
| Nov-29-18 | Downgrade | Janney | Buy → Neutral |
| Oct-31-18 | Upgrade | Janney | Neutral → Buy |
| Nov-07-17 | Downgrade | Janney | Buy → Neutral |
| Nov-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-31-17 | Resumed | BTIG Research | Buy |
| Nov-14-16 | Resumed | Leerink Partners | Outperform |
| Dec-18-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-11-15 | Reiterated | Leerink Partners | Outperform |
| Nov-26-13 | Initiated | William Blair | Outperform |
View All
Veracyte Inc Stock (VCYT) Latest News
Veracyte, Inc. (NASDAQ:VCYT) CFO Rebecca Chambers Sells 527 Shares - MarketBeat
Veracyte CFO Rebecca Chambers sells $23,108 in stock By Investing.com - Investing.com Australia
Veracyte, Inc. (NASDAQ:VCYT) Shares Purchased by Jennison Associates LLC - MarketBeat
Insider Sell: Rebecca Chambers Sells Shares of Veracyte Inc (VCY - GuruFocus.com
Veracyte CFO Rebecca Chambers sells $23,108 in stock - MSN
New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer - BioSpace
Clinical Study: Revolutionary Bladder Cancer Test Predicts Disease Progression with 33% Higher Accuracy - StockTitan
Cancer Diagnostics Leader Veracyte Schedules Critical Year-End Financial Results - StockTitan
Veracyte (NASDAQ:VCYT) Sets New 52-Week High After Analyst Upgrade - MarketBeat
6,621 Shares in Veracyte, Inc. (NASDAQ:VCYT) Purchased by Baader Bank Aktiengesellschaft - MarketBeat
Veracyte (NASDAQ:VCYT) Rating Lowered to Hold at StockNews.com - MarketBeat
Needham & Company LLC Issues Positive Forecast for Veracyte (NASDAQ:VCYT) Stock Price - MarketBeat
Veracyte Stock Soars to 52-Week High, Reaching $46.12 - MSN
Veracyte stock price target raised to $51 at Needham - MSN
Veracyte Stock Soars to 52-Week High, Reaching $46.12 By Investing.com - Investing.com Canada
Veracyte stock price target raised to $51 at Needham By Investing.com - Investing.com Canada
Demystifying Veracyte: Insights From 7 Analyst Reviews - Benzinga
Needham Boosts Price Target on Veracyte to $51 From $44, Keeps Buy Rating -January 29, 2025 at 07:55 am EST - Marketscreener.com
Exchange Traded Concepts LLC Has $2.75 Million Stock Position in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
AEGON ASSET MANAGEMENT UK Plc Sells 39,048 Shares of Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Assenagon Asset Management S.A. Decreases Stake in Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Brokerages Set Veracyte, Inc. (NASDAQ:VCYT) Target Price at $41.13 - MarketBeat
Veracyte, Inc. (NASDAQ:VCYT) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by AMI Asset Management Corp - MarketBeat
Legal Advantage Investments Inc. Makes New $250,000 Investment in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Avanza Fonder AB Makes New $1.38 Million Investment in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
StockNews.com Upgrades Veracyte (NASDAQ:VCYT) to “Buy” - Defense World
Veracyte (NASDAQ:VCYT) Stock Rating Upgraded by StockNews.com - MarketBeat
First Week of September 19th Options Trading For Veracyte (VCYT) - Nasdaq
Veracyte Inc (VCYT) Shares Gap Down to $40.865 on Jan 14 - GuruFocus.com
Cathie Wood's Ark Invest Trims Palantir Again As Peter Thiel Co-Founded Firm's Stock Tumbles Nearly 15% In 2025 - Benzinga
JPMorgan Chase & Co. Has $11.80 Million Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT) - Defense World
Harbor Capital Advisors Inc. Reduces Position in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Catherine Wood's Strategic Reduction in Veracyte Inc Shares - GuruFocus.com
Diversified Trust Co Cuts Stake in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat
Veracyte, Inc. (NASDAQ:VCYT) Has Found A Path To Profitability - Yahoo Finance
Veracyte Gains 44% in a Year: What's Driving the Stock? - MSN
The Zacks Rank Explained: How to Find Strong Buy Medical Stocks - Yahoo Finance
Veracyte director Karin Eastham sells shares worth $403,005 By Investing.com - Investing.com Australia
Insider Selling: Veracyte, Inc. (NASDAQ:VCYT) Director Sells 10,000 Shares of Stock - MarketBeat
Veracyte director Karin Eastham sells shares worth $403,005 - Investing.com
Veracyte Inc Stock (VCYT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):